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Abstract
Background: The ‘classic’ organic acidaemias (OAs) (propionic, methylmalonic and isovaleric) typically present in
neonates or infants as acute metabolic decompensation with encephalopathy. This is frequently accompanied by
severe hyperammonaemia and constitutes a metabolic emergency, as increased ammonia levels and accumulating
toxic metabolites are associated with life-threatening neurological complications. Repeated and frequent episodes
of hyperammonaemia (alongside metabolic decompensations) can result in impaired growth and intellectual
disability, the severity of which increase with longer duration of hyperammonaemia. Due to the urgency required,
diagnostic evaluation and initial management of patients with suspected OAs should proceed simultaneously.
Paediatricians, who do not have specialist knowledge of metabolic disorders, have the challenging task of facilitating a
timely diagnosis and treatment. This article outlines how the underlying pathophysiology and biochemistry of the
organic acidaemias are closely linked to their clinical presentation and management, and provides practical advice for
decision-making during early, acute hyperammonaemia and metabolic decompensation in neonates and infants with
organic acidaemias.
Clinical management: The acute management of hyperammonaemia in organic acidaemias requires administration
of intravenous calories as glucose and lipids to promote anabolism, carnitine to promote urinary excretion of urinary
organic acid esters, and correction of metabolic acidosis with the substitution of bicarbonate for chloride in
intravenous fluids. It may also include the administration of ammonia scavengers such as sodium benzoate or sodium
phenylbutyrate. Treatment with N-carbamyl-L-glutamate can rapidly normalise ammonia levels by stimulating the first
step of the urea cycle.
Conclusions: Our understanding of optimal treatment strategies for organic acidaemias is still evolving. Timely
diagnosis is essential and best achieved by the early identification of hyperammonaemia and metabolic acidosis.
Correcting metabolic imbalance and hyperammonaemia are critical to prevent brain damage in affected patients.
Keywords: Metabolic acidosis, Hyperammonaemia, Organic acidaemias, Metabolic decompensation, Biochemical
pathogenesis
Background
Organic acidaemias (OAs), a group of rare, inherited,
metabolic disorders, typically present in neonates or
infants as acute, potentially life-threatening, metabolic de-
compensation [1–3], which follows an initial symptom-
free period of a few days [3, 4]. An increase in plasma am-
monia to toxic levels is often a key feature of metabolic
decompensation [5, 6], which needs to be addressed
promptly since it can lead to life-threatening neurological
complications [7]. Paediatricians, who do not have special-
ist knowledge of metabolic disorders, have the challenging
task of initiating treatment while obtaining a timely diag-
nosis. This article provides practical advice to help with
the decision-making and clinical management of hyper-
ammonaemia during early, acute metabolic decompensa-
tion in neonates and infants with OAs.
Although more than 65 different OAs have been de-
scribed, even the more common ones are rarely
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encountered by paediatricians, as the collective incidence
is about 1 in 3000 live births [8]. The initial signs and
symptoms of metabolic decompensation – such as poor
feeding, vomiting, dehydration and lethargy – are
non-specific and can mimic other conditions, such as bac-
terial sepsis [3], thereby making rapid identification and
intervention to prevent irreversible neurological sequelae
[3, 4] particularly challenging. Elevated plasma ammonia
levels have a direct impact on neurological outcomes [3,
9], with levels above 200 μmol/L usually being associated
with drowsiness and lethargy (impaired vigilance) [5].
This article describes the three OAs most likely to result
in hyperammonaemia during acute metabolic decompen-
sation: propionic acidaemia (PA; MIM# 606054), methyl-
malonic acidaemia (MMA; MIM# 251000) and isovaleric
acidaemia (IVA; MIM# 243500). Together with maple
syrup urine disease, PA, MMA and IVA are sometimes re-
ferred to as ‘classic’ OAs [10]. Other OAs cause typical
biochemical changes identified through newborn screen-
ing and have different clinical implications. While hyper-
ammonaemia is an important manifestation of PA, MMA
and IVA, its clinical significance needs to be considered
together with other abnormalities, such as acidosis, keto-
sis, and lactic acidaemia, as well as distinguishing it from
the hyperammonaemia caused by urea cycle disorders
(UCDs) [11], the main group of conditions from which
OAs must be differentiated [3, 12, 13]. Not all patients
with PA, MMA or IVA present with hyperammonaemia,
but most develop it in the newborn period, and continue
to have recurrent episodes of hyperammonaemia during
metabolic decompensation [3, 14].
This article considers the pathophysiology and under-
lying biochemical pathogenesis of OAs, and the diagnos-
tic and clinical management of hyperammonaemia in
PA, MMA and IVA. Two case studies illustrate the clin-
ical presentation, key diagnostic evaluations and treat-
ment in a neonate with acute decompensation and in a
child with chronically elevated ammonia levels.
Clinical presentation of OAs
The development of an acute, life-threatening illness in
a previously apparently healthy neonate is a strong indi-
cator of an inherited metabolic disorder [15]. At initial
presentation of neonates, the normal diet of breast milk
or formula, together with postpartum catabolism, causes
acute decompensation. In patients with OAs beyond the
neonatal period, acute attacks are usually triggered by
conditions that increase catabolism, such as fasting,
vomiting or febrile infections (Table 1) [5, 13, 16].
In the newborn period, poor feeding, vomiting, dehydra-
tion, lethargy, tachycardia and hypothermia (Table 1) usu-
ally develop within 2–7 days after birth [3, 13] and, if left
untreated, can quickly progress to respiratory distress,
coma and death [16, 17]. However, as these symptoms are
also observed in more common conditions, such as infec-
tion, a high index of suspicion should be maintained [18].
If there is neurological involvement [3, 19], routine labora-
tory studies for OAs (chemistry profile, ammonia level)
should be performed at the same time as the septic
work-up.
After the neonatal period, OAs may present with delays
in development, failure to thrive, altered mental state, ab-
normal tone, seizures and motor dysfunction [16, 20, 21].
Other signs and symptoms of acute or chronic decompen-
sation can include weight loss (often seen in newborns)
and bone-marrow suppression in PA and MMA, and the
characteristic ‘sweaty feet’ odour in patients with IVA [16,
22–24].
Table 1 Triggers, clinical signs and symptoms, and biochemical signs of acute decompensation in PA and MMA [3]
Triggers Clinical signs and symptoms Biochemical signs
Infection Poor feeding Metabolic acidosis:
• pH < 7.3
• anion gap > 20 mmol/L
• low HCO3
− or base excess <−5 mmol/L)
Fever Vomiting
Prolonged fasting Lethargy
Medication (e.g. chemotherapy,
high-dose glucocorticoids)
Seizures
Surgery and/or general anaesthesia Irritability Elevated blood lactate (> 3 mmol/L)
Acute trauma Respiratory distress Hyperammonaemia:
• > 75 μmol/L associated with symptomatic decompensation
• > 200 μmol/L associated with impaired vigilance [5]Significant haemorrhage Hypothermia
Psychological stress Dehydration
Excessive protein intake Weight loss
Excessive physical exertion Ketonuria (> trace in infants or > + in children)
Neutropenia
Thrombocytopenia
Abbreviation: HCO3
− Bicarbonate, MMA Methylmalonic acidaemia, PA Propionic acidaemia
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Biochemical pathogenesis of OAs
All the classical OAs are inherited as autosomal recessive
traits [17] and are caused by a deficiency in the enzymes
involved in breaking down amino acids (isoleucine, valine,
methionine and threonine in PA and MMA, and leucine
in IVA) and additional substrates (odd-chain fatty acids,
cholesterol, nucleotides in PA and MMA) [14, 16, 17, 25,
26] (Fig. 1). PA is caused by a deficiency in propionyl-co-
enzyme A (CoA) carboxylase, composed of alpha and beta
subunits encoded by the PCCA and PCCB genes,
respectively [17]. MMA can be caused by a deficiency of
multiple enzymes affecting either the transformation of
cobalamin to adenosylcobalamin, or the activity of
methylmalonyl-CoA mutase, or racemase [16, 17, 27, 28].
IVA is caused by a deficiency in isovaleryl-CoA
dehydrogenase [16, 17]. Each enzyme deficiency leads to a
build-up of its precursor(s): propionyl-CoA (P-CoA) in
PA, P-CoA and methylmalonyl-CoA in MMA, and
isovaleryl-CoA in IVA [16, 29], and the corresponding or-
ganic acids once released from CoA (Fig. 1).
Hyperammonaemia likely results from the interaction
of the substrates for the defective enzymes with other
biochemical pathways, including the urea and tricarb-
oxylic acid (TCA) or Krebs cycles (Fig. 1) [2, 17, 29]. In
the urea cycle, a series of enzymes and transporters fa-
cilitate the incorporation of ammonia (as the amino
group of carbamyl phosphate and aspartate) into urea
for urinary excretion (Fig. 1). The complete urea cycle is
mostly active in the liver, where, under physiological
conditions, ammonia is removed in the mitochondrial
Fig. 1 Proposed biochemical pathogenesis of organic acidaemias: propionic acidaemia, methylmalonic acidaemia, isovaleric acidaemia. Genetic
defects in enzymes involved in the breakdown of amino acids cause the accumulation of toxic organic acids with disruption of the tricarboxylic
acid and urea cycles. Propionic acidaemia is caused by propionyl-CoA carboxylase deficiency, and methylmalonic acidaemia results from
methylmalonyl-CoA mutase deficiency [16, 17]. Isovaleric acidaemia is caused by isovaleryl-CoA dehydrogenase deficiency, which is involved in
leucine catabolism. Rectangles indicate key affected enzymes: green rectangles indicate the primary affected enzymes (propionyl-CoA carboxylase,
methylmalonyl-CoA mutase, isovaleryl-CoA dehydrogenase); blue solid rectangles are positions of primary enzyme blocks. Blue crosses indicate secondary
enzyme inhibition; blue texts are enzyme precursors; orange diamonds are key enzyme co-factors. Abbreviations: 2-MCA 2-methylcitrate, CoA coenzyme
A, CPS-1 carbamyl phosphate synthetase-1, GLN glutamine, GLU glutamate, H2O water, IV-CoA isovaleryl-CoA, IVD isovaleryl-CoA dehydrogenase, LEU
leucine, MM-CoA methylmalonyl-CoA, MUT methylmalonyl-CoA mutase, NAG N-acetylglutamate, NAGS N-acetylglutamate synthase, NH3 ammonia, PC
pyruvate carboxylase, PCC propionyl-CoA carboxylase, P-CoA propionyl-CoA, PDH pyruvate dehydrogenase complex, TCA tricarboxylic acid, VAL valine.
Modified from Kölker et al. 2013 [2], Schiff et al. 2016 [17], and Vianey-Saban et al. 2006 [29]
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matrix and cytosol of periportal hepatocytes [30].
N-acetylglutamate synthase (NAGS; EC 2.3.1.1) catalyses
the formation of N-acetylglutamate (NAG) from glutam-
ate and acetyl-CoA; NAG is an essential activator for the
first enzyme in the urea cycle (carbamyl phosphate syn-
thetase 1; CPS-1). Ammonia that escapes the urea cycle
in periportal hepatocytes conjugates with glutamate to
form glutamine in pericentral hepatocytes, explaining
the increase in glutamine seen in all UCDs [30]. The
urea cycle interacts with other mitochondrial pathways
such as the TCA cycle, fatty acid oxidation and amino
acid catabolism (Fig. 1) [2, 17, 29]. The TCA cycle en-
ables the extraction of reducing equivalents from
acetyl-CoA that fuel the mitochondrial electron trans-
port chain to generate adenosine triphosphate through
oxidative phosphorylation. The TCA and urea cycles are
linked at oxaloacetate, the start and end point of the
TCA cycle (Fig. 1), where oxaloacetate can be converted
to aspartate via transamination [2, 29]. In addition, glu-
tamate can be generated from 2-oxoglutarate and am-
monia during physiological cataplerosis [2, 17, 29]. The
oxidation of fatty acids, carbohydrates and amino acids
generates acetyl-CoA, one of the substrates necessary for
NAG synthesis [31, 32].
In OAs, the accumulated metabolites (P-CoA,
methylmalonyl-CoA and isovaleryl-CoA) compete with
acetyl-CoA to inhibit the activity of NAGS [12, 33, 34],
thereby diminishing the synthesis of carbamyl phosphate
[35]. This secondary impairment of the urea cycle can
lead to elevated ammonia levels with neurotoxic effects
during metabolic decompensation in OAs [12, 29, 36].
In contrast, the hyperammonaemia observed in UCDs is
caused by primary defects in urea cycle enzymes or
transporters [32].
The end point of propionic and methylmalonic acid me-
tabolism is the generation of succinyl-CoA, an important
intermediate of the TCA cycle [16]. This degradation
pathway (anaplerosis) represents an important mechanism
for replenishing TCA cycle intermediates [13]. Since ana-
plerosis is disrupted in PA and MMA, TCA cycle interme-
diates must be derived from other pathways. For instance,
glutamine can be cleaved to form ammonia and glutam-
ate; this in turn splits into ammonia and 2-oxoglutarate,
which can then enter the TCA cycle (Fig. 1) [13]. A
by-product of these reactions is the release of ammonia,
which may contribute to the chronic hyperammonaemia
observed in these disorders. In addition, the reduced con-
centration of glutamate might further impair synthesis of
NAG by NAGS. Finally, the flow of glutamine to
α-ketoglutarate to replenish the TCA cycle results in a de-
crease, rather than an increase, in glutamine levels in PA
as ammonia levels increase [13].
Hyperammonaemia toxicity in the developing brain is
due to multifactorial mechanisms, including disruption
of amino acid and cerebral energy metabolism, and in-
creased oxidative stress [36]. Excess propionic and
methylmalonic acid levels also appear to contribute dir-
ectly to progressive neurological deterioration by acting
through protein kinases and phosphatases to interfere
with cytoskeletal assembly in neuronal and glial cells [8],
as well as disrupting the mitogen-activated protein kin-
ase and p53 signalling pathways that promote apoptosis
of neuronal cells [8, 37].
In addition to propionic acid and methylmalonic acid,
other toxic metabolites such as propionylcarnitine and
methylcitric acid can also disrupt the normal functioning
of the TCA cycle [8, 12]. There is increasing evidence to
suggest that the significant disruption of mitochondrial
function – involving multiple deficiencies in oxidative
phosphorylation via the mitochondrial electron transport
chain, secondary to inhibition of the TCA cycle [25, 38]
– culminates in a synergistic impairment of energy me-
tabolism and depletion of cellular energy stores [2, 29].
Elevated levels of propionic acid, methylmalonic acid
and isovaleric acid appear to directly mediate oxidative
stress by increasing levels of reactive oxygen species
(ROS) [8], and reducing ROS-protective levels of gluta-
thione [39]. This further contributes to the intra- and
extracerebral disease manifestations of the classical OAs
[2]. Mitochondrial electron transport chain dysfunction
has been linked to damage in the basal ganglia [1, 19,
25]; it has been suggested that methylcitric acid may be
more neurotoxic than methylmalonic acid [40]. In
addition, intracellular metabolite accumulation leads to
CoA sequestration and its subsequent depletion, result-
ing in detrimental effects primarily in mitochondria [41].
Clinical consequences and complications
Developmental delays are common in OAs, with some
patients showing progressive neurological deterioration
with increasing age. In a retrospective study of 55 pa-
tients with PA (median age 5.2 years), 75.5% showed
some degree of intellectual disability, with a median IQ
of 55 [42]. Another study in 80 patients with classical
OAs, found that PA was associated with the worst
neurological prognosis: 37% of patients had abnormal
neurological findings, 61% had abnormal psychometric
scores, and 56% had basal ganglia lesions. In contrast, all
patients with IVA had normal neurological examina-
tions, only 18% had psychometric impairment, and only
17% had basal ganglia lesions [43].
OAs are also associated with long-term systemic ef-
fects in other organs with high energy requirements,
such as the heart, kidneys, eyes [12, 25, 44, 45], pancreas
[22] and bone marrow [23]. These extracerebral compli-
cations are apparently related to the synergistic effects of
toxic metabolites and impaired mitochondrial oxidative
phosphorylation [2, 25], often occur despite good
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metabolic control, and can appear in asymptomatic indi-
viduals [2, 12, 42, 46]. This may be related to sequestration
of CoA within mitochondria, depletion of mitochondrial
DNA, increased production of ROS, and alterations in
gene expression [2]. Dysfunction of the mitochondrial
electron transport chain may contribute to late
multi-organ complications in PA and MMA [25], includ-
ing the formation of megamitochondria in kidney prox-
imal tubules, seen in MMA patients with chronic kidney
disease [38]. For patients with PA, the depletion of carni-
tine and the sequestration of CoA by excess organic acids
are further responsible for decreases in fatty acid oxidation
and acetyl-CoA production [29, 41], in turn leading to fur-
ther secondary inhibition of the urea and TCA cycles [29],
and contributing to long-term cardiomyopathy [12].
Clinical management and decision-making in OAs
Table 2 provides a clinical checklist aimed at paediatri-
cians who are unfamiliar with OAs. This checklist com-
plements current guidance [3] and outlines symptoms
that may relate to an underlying diagnosis, laboratory
testing requirements, clinical laboratory findings (Table 1),
and immediate management recommendations for pa-
tients with OAs.
Diagnosis
To prevent the risk of neurological sequelae, treatment of
OAs should be initiated as soon as the condition is sus-
pected. Advice from a metabolic specialist should be
sought quickly to allow simultaneous diagnostic work-up
and initial management [3]. Routine clinical laboratory in-
vestigations often show metabolic acidosis, increased
anion gap, hyperammonaemia, ketosis, and lactic acidosis
(Table 1) [3, 15, 47]. OAs are diagnosed biochemically by
analysing the levels of organic acids in urine, with add-
itional information derived from the plasma acylcarnitine
and amino acid profiles (the latter to exclude UCDs); acyl-
carnitine results may be the first available. In urine, signifi-
cant elevations of methylcitric acid in the absence of
elevated MMA is diagnostic of PA [3]. In MMA, methyl-
malonic acid is markedly increased, and methylcitric acid
may be minimally elevated. Elevated concentrations of
3-hydroxyisovaleric acid and isovalerylglycine are charac-
teristic of IVA [48, 49]. The duration of hyperammonae-
mia, abnormal acid-base balance with metabolic acidosis
(decreased pH and bicarbonate with increased anion gap),
and the duration of coma correlate with poor neurological
outcomes. In a sick infant, these abnormalities should be
corrected as rapidly as possible.
OAs must be differentiated from UCDs. In both cases,
patients usually present with neurological symptoms and
hyperammonaemia [50]. The presence of metabolic acid-
osis and ketonuria suggests OA in neonates (Table 3),
whereas respiratory alkalosis is often seen in UCDs [15].
Plasma amino acids can pinpoint specific abnormalities in
the urea cycle. Glutamine is typically high in UCDs and
can be low to normal in OAs; glycine may be elevated in
Table 2 Clinical checklist: acute management of organic
acidaemia (modified from Baumgartner et al. 2014 [3])
• Acute management is required any time a patient with an organic
acidaemia has symptoms such as lethargy, vomiting, tachypnoea, and
impaired vigilance.
• Laboratory testing (metabolic panel with ammonia, electrolytes, anion
gap, lactate, ketone bodies in urine) can determine whether the
patient needs urgent care. Plasma amino acids, urine organic acids and
plasma acylcarnitine profile are useful to establish the cause of acute
metabolic decompensation and to monitor long-term patient management.
• Immediate administration of sufficient calories (100–120 kcal/kg/day in
infants, with lower amounts in older children) in the form of glucose
and lipids is necessary during acute decompensation in organic
acidaemias, although protein should be restarted as soon as possible
(usually not later than 24–48 h). As the patient improves, a nasogastric
tube should be inserted to administer enteral formulas containing limited
amounts of proteins (0.5 g/kg/day). Enteral feeds should be gradually
increased to provide adequate calories (100–120 kcal/kg/day in infants,
with lower requirements in older children) and protein (increasing natural
protein to 0.8–1.2 g/kg/day and then adding the balance of protein
needed via medical foods without propionic acid precursors to reach the
recommended daily allowance for age).
• Intravenous glucose may be given as 10% dextrose (D10), or 20%
dextrose (D20) if a central line is available, together with appropriate
salts (half-normal saline up to about 5 years of age, normal saline after
5 years of age; potassium chloride at 20 mEq/L if there is no evidence
of hyperkalaemia), and intralipids 20% to provide adequate calories
for age.
• In case of metabolic acidosis (sodium bicarbonate < 15mEq/L), sodium
bicarbonate is substituted for sodium chloride (75mEq/L or 150mEq/L),
and potassium acetate (20mEq/L) is substituted for potassium chloride.
Serum bicarbonate and electrolytes should be monitored every 4–6 h
and intravenous sodium bicarbonate should be switched to sodium
chloride once serum bicarbonate reaches 25mEq/L.
• If glucose becomes greater than 8.3 mmol/L, insulin should be given:
0.1 U/kg as a bolus, followed by 0.1 U/kg/hour as a drip. Insulin dose
should be adjusted to maintain glucose levels 3.9–8.3 mmol/L.
Table 3 Clinical laboratory findings in patients with PA, MMA,
or UCDs (modified from Baumgartner et al. 2014 [3])
PA/MMA UCDs
Hyperammonaemia + to ++ ++
Acidosis + +/−
Ketonuriaa ++/+++ –
Hypoglycaemia +/− –
Increased lactateb + –
Increased AST and ALT +/− +
Increased uric acid + –
Decreased blood cell counts + –
Abbreviations: ALT Alanine transaminase, AST Aspartate transaminase, MMA
Methylmalonic acidaemia, PA Propionic acidaemia, UCDs Urea cycle disorders
aKetonuria ++/+++ suggests OA in neonates
bPlasma lactate > 6 mmol/L (levels of 2–6 mmol/L may be due to severe crying
or extensive muscle activity)
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both conditions [3, 50, 51]. However, it is important to ex-
clude non-ketotic hyperglycinaemia, which can also cause
encephalopathy in infants [52]. Urine orotic acid, mea-
sured as part of the urine organic acids profile or by separ-
ate analysis, is elevated in the most common UCD
(X-linked ornithine transcarbamylase deficiency), but is
normal or only minimally elevated in NAGS or CPS-1 de-
ficiencies and in all OAs [32, 53].
Acute management
Current guidelines for managing OAs focus on PA and
MMA [3]. The initial aim of therapy is to reverse en-
dogenous catabolism and provide sufficient energy to pro-
mote anabolism [3]. Sufficient calories should be provided
by intravenous glucose and lipids to prevent further catab-
olism, and metabolic acidosis can be corrected by substi-
tuting bicarbonate and acetate for chloride in intravenous
(IV) solutions. Infants require 100–120 kcal/kg/day, with
lower requirements in older children. Insulin should be
used to correct the hyperglycaemia caused by the adminis-
tration of IV glucose and to reverse catabolism; it is im-
portant to monitor serum/plasma phosphate, magnesium,
calcium and potassium during administration of IV insu-
lin and to promptly correct electrolytic imbalance.
As amino acids are the primary precursors of organic
acids, protein intake should be transiently stopped
(maximum 24–48 h) [3]. Carnitine (recommended dosage
of 200mg/kg/day) should be given to promote the urinary
excretion of organic acid-carnitine esters. As the patient
improves, a nasogastric tube should be inserted to adminis-
ter enteral formulas containing limited amounts of proteins
(0.5 g/kg/day). Enteral feeds should be gradually increased
to provide adequate calories (100–120 kcal/kg/day in in-
fants, with lower requirements in older children) and pro-
tein (increasing natural protein to 0.8–1.2 g/kg/day and
then adding the balance of protein needed via medical
foods without propionic acid precursors to reach the rec-
ommended daily allowance for age) [3].
There are currently no specific guidelines for managing
IVA. In general, the management approach for this OA is
similar to that for PA or MMA except that leucine restric-
tion and glycine supplementation are introduced to re-
duce the accumulation of isovaleric acid and promote its
excretion [54, 55].
Sodium benzoate or sodium phenylbutyrate are the
mainstay of ammonia detoxification in patients with
UCDs. These medications provide an alternative pathway
for nitrogen excretion through CoA-dependent enzymatic
reactions. Sodium benzoate binds to glycine to form hip-
puric acid, and sodium phenylbutyrate is first metabolised
to phenylacetate, which binds to glutamine to form pheny-
lacetylglutamine. Both hippuric acid and phenylacetylglu-
tamine are excreted in the urine. Sodium benzoate is also
used sometimes in patients with PA and MMA. For pa-
tients with undiagnosed symptomatic hyperammonaemia
(> 150–< 250 μmol/L for neonates; 100–250 μmol/L for
non-neonates) [3], current guidance recommends the use
of sodium benzoate or sodium phenylbutyrate [3, 7, 12].
Unlike UCDs, these therapies should be used with caution
in patients with OAs, because glutamine levels can already
be low due to the abnormal functioning of the TCA cycle
in PA and MMA [3, 12].
Treatment with N-carbamyl-L-glutamate (NCG; Car-
baglu®, Orphan Europe), a stable synthetic analogue of
NAG, the essential co-factor of CPS-1, can stimulate the
first step of the urea cycle (Fig. 1), enabling the forma-
tion of carbamyl phosphate and reducing ammonia
levels in patients with secondary hyperammonaemia [6,
56, 57]. Two retrospective observational studies [35, 58]
and case reports [56, 59, 60] indicate that NCG can re-
duce ammonia levels in neonates and older patients with
PA, MMA or IVA, irrespective of the use of scavenger
medication [6]. NCG is recommended for the manage-
ment of patients with undiagnosed symptomatic hyper-
ammonaemia, and is also included in the 2014 European
guidance for managing PA and MMA [3].
Haemodialysis can be used in severely encephalopathic
patients with hyperammonaemia who are not respond-
ing to medical management [35].
Long-term management
The aims of long-term OA management are to prevent
episodes of metabolic decompensation, minimise com-
plications, and promote normal growth and develop-
ment [3, 61]. This involves a threefold approach: dietary
management; drug therapy; and life-long monitoring to
identify and treat potential complications, such as pan-
creatitis, renal impairment, cardiomyopathy, cardiac ar-
rhythmias and osteoporosis [12].
Low-protein diets are an essential part of long-term man-
agement for all classical OAs [61, 62]. Patients with PA or
MMA should also receive supplementation with precursor-
free synthetic amino acid mixtures, vitamins, minerals and
fats [61, 63]. In general, infants and young children require
0.8–1.2 g/kg/day of natural protein, with the balance of pro-
tein requirement coming from medical foods not contain-
ing propionic acid precursors, in order to achieve the
recommended daily allowance appropriate for age. After 2
years of age, some children with methylmalonic acidaemia
can continue with protein restriction alone, with the bal-
ance of calories provided by protein-free foods.
The most commonly used treatments are L-carnitine, vita-
min B12 (as hydroxocobalamin in cobalamin-responsive
MMA), and intermittent antibiotics (e.g. metronidazole)
to reduce intestinal flora producing propionic acid [3].
Citrate supplementation (7.5mEq/kg/day), which can buf-
fer metabolic acidosis and replenish the TCA cycle, may
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also be beneficial in PA [64]. In patients with IVA,
long-term management also typically involves glycine and
carnitine supplementation in addition to a low-protein
diet [54, 55, 65, 66]. Patients with OAs in good metabolic
control, intended as the adequate provision of calories
with limited amounts of protein and the supplements
listed above, are usually clinically stable (although with
mildly elevated ammonia levels in some cases). Metabolic
control in many cases requires the use of a gastrotomy
tube, which facilitates the administration of calories and of
feeds at night to prevent catabolism. This precarious equi-
librium can be altered by persistent vomiting or intercur-
rent infections, which can decrease calorie intake and
increase calorific needs, leading to hyperammonaemia
and, in some cases, metabolic acidosis.
NCG may also be effective in the long-term treatment
in patients with severe PA and MMA with recurrent epi-
sodes of hyperammonaemia [67]. In a recent study, eight
patients with PA or MMA who had experienced between
three and 11 episodes of decompensation in the preceding
year were treated with NCG (50mg/kg/day) for 7–16
months. Treatment with NCG markedly decreased the
number and severity of decompensation episodes, with
three patients experiencing no additional episodes during
treatment, and with all episodes in the remaining patients
becoming amenable to treatment at home [67].
In a separate published case report, one patient had ex-
perienced 78 admissions for decompensations during the
first 9 years of life, with 7–10 admissions per year [68].
Continuous treatment with NCG was initiated at 9 years
of age at 100mg/kg/day with a dose reduction to 50mg/
kg/day after 6 months. In the period from 9 to 15 years of
age, the patient experienced only two episodes of acute
decompensation requiring hospitalisation, both of which
occurred during the first year of treatment with NCG.
While these findings provide some evidence for the
long-term role of NCG in patients with severe PA and
MMA who experience recurrent episodes of hyperammo-
naemia, there are no double-blind, placebo-controlled
studies available. Consideration also needs to be given to
reports of NCG being ineffective in OAs [57], indicating
the need for more studies exploring the long-term effects
of NCG on hyperammonaemia in OAs.
In patients with PA or MMA who experience repeated
metabolic decompensation, or in whom the disease is dif-
ficult to manage with diet and pharmacological therapy,
liver transplantation can reduce the number of hospitali-
sations and improve quality of life [3, 12]. Although liver
transplantation may reduce the risk of certain complica-
tions, such as cardiomyopathy, it has no effect on the risk
of neurological or ophthalmological complications, and, of
course, has associated risks of mortality [3, 12]. For some
adult patients with MMA-related end-stage kidney dis-
ease, renal transplantation is also indicated [12].
Case studies
The following cases illustrate: (1) the diagnostic work-up
and initial management of acute decompensation in a
2-day-old neonate; (2) the diagnostic work-up and initial
and long-term management of chronically elevated
blood ammonia in an infant aged 9months at diagnosis.
Case study 1: acute decompensation in the neonatal period
A 2-day-old girl presented with poor feeding, dehydra-
tion and lethargy progressing to coma. Initial laboratory
investigations indicated severe metabolic acidosis and
hyperammonaemia. The patient was intubated and given
intravenous fluids containing glucose, sodium bicarbon-
ate (75 mEq/L), potassium acetate (20 mEq/L), intralipids
(20%) and insulin (starting with a 0.1 U/kg bolus,
followed by 0.1 U/kg/hour) to maintain glucose levels at
3.9–8.3 mmol/L. The key to treatment is to provide suf-
ficient calories (110–120 kcal/kg/day) with the above
fluids without creating osmotic imbalances.
Ammonia levels normalised within 12 h and the patient
was subsequently diagnosed with PA by urine organic acid
analysis (3-OH-propionic acid = 5010mmol/mol creatin-
ine; methylcitric acid = 1982mmol/mol creatinine). The
plasma acylcarnitine profile indicated elevated propionyl-
carnitine (11.78 μmol/L; normal = < 0.55 μmol/L) with low
levels of free carnitine (4 μmol/L; normal = 22–63 μmol/
L). Figure 2 shows the progressive normalisation of serum
bicarbonate (A) (normal range 20–26mmol/L) and am-
monia (B) (normal range 20–99 μmol/L in newborns) after
starting intravenous therapy.
Case study 2: chronically elevated blood ammonia in a
young child
A 6.5-year-old boy was diagnosed with PA at 9months of
age during selective metabolic screening for intellectual
disability. Ammonia was elevated (maximum 105 μmol/L)
at diagnosis, but levels returned to the normal range
(< 48 μmol/L) after corrective treatment (diet and carni-
tine supplementation at 100mg/kg/d in two doses). Over
the course of the following years, the patient had episodes
of hyperammonaemia (maximum level: 378 μmol/L)
that rapidly normalised after the administration of a
single dose of sodium benzoate (200 mg/kg/dose given
over 90 min).
For the majority of the measurements during the first
year after diagnosis, ammonia levels taken during
outpatient clinic visits were elevated in the range of
70–140 μmol/L), but there were no signs of acute hyper-
ammonaemia and so no specific treatment was adminis-
tered. These ammonia elevations were not considered to
be causing a clinical problem, and were rather interpreted
as an indication of suboptimal metabolic stability. There-
fore, ammonia elevations were managed by optimising the
patient’s diet and nutritional status.
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About 1 year after diagnosis, the patient received a gas-
trostomy tube. This facilitated dietary management to a
large extent and, in particular, ensured a sufficient daily in-
take of calories. Once this was established, metabolic sta-
bility was much improved (Fig. 3). From diagnosis, the
patient was given a low-protein diet, according to current
guidelines [3]: initial natural protein intake was 0.9 g/kg/d
but was gradually increased to 1.24 g/kg/d at age 5 years.
Synthetic protein intake started at 0.8 g/kg/d and was
gradually reduced to 0.24 g/kg/d at 6.5 years of age. This
was done according to plasma amino acid monitoring and
closely following the safe levels of protein recommenda-
tions in the Food and Agriculture Organization of the
United Nations/World Health Organization/United
Nations University expert consultation (2007) [69] (as de-
tailed in [3]).
Conclusions
Hyperammonaemia, frequently observed in the classical
OAs (PA, MMA and IVA), is most often associated with
metabolic decompensation in the neonatal period, and
contributes to the risk of neurological damage. Timely
diagnosis and intervention is essential, as prognosis is
strongly linked to elevated blood ammonia levels and
duration of coma, as well as to the increased levels of
specific organic acids. Prompt evaluation from a meta-
bolic specialist is required, but should not delay inter-
vention, diagnostic work-up and initial management.
While the diagnosis of OAs remains challenging be-
cause of the low incidence of these disorders, as well as
their variable and non-specific presentation, recent ad-
vances in diagnostic techniques, such as newborn
screening by tandem mass spectrometry [11], which
Fig. 2 Normalisation of serum bicarbonate (a) and ammonia (b)
after starting intravenous therapy in a 2-day-old neonate with acute
decompensation of propionic acidaemia. Normal range is indicated
by the shaded area
Fig. 3 Plasma ammonia concentrations in a 6.5-year-old patient over a time period of 5.5 years after diagnosis was made at age 9 months.
Concentrations are given in μmol/L and normal range is indicated by a shaded area
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allow earlier identification, are encouraging. Screening of
neonates for OAs and other inherited metabolic disor-
ders offers the potential for early diagnosis and therapy
[63]; however, newborn screening is not offered in all
countries, and evidence that screening improves
long-term outcomes is currently limited [1, 14, 50, 63,
69]. In many cases of OAs, results become available after
newborns are already symptomatic.
With the diverse range of interventions in OAs, timely
diagnosis by the identification of elevated ammonia
levels and metabolic acidosis can allow their rapid cor-
rection, which is critical for the prevention of brain
damage [46, 50].
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